Thanks to its capacity to modulate BCL-2 and BCL-2-like protein levels, and to block IRF4/MYC signaling, CPI203 also exerted notable activity either as single agent or in combination with the BCL-2 antagonist venetoclax in MYC+/BCL2+ DHL [70], or combined with the proteasome inhibitor bortezomib or lenalidomide in bortezomib-resistant MCL [66]. Here, MYC is linked to mantle cell lymphoma.